Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.
The company is currently developing a pipeline of drug candidates consisting of OncoMimics™ peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with recurrent glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.
Company Details
- Employees
- 42
- Founded
- -
- Address
- 94-96 Avenue Ledru-Rollin, Paris,75011,france
- Phone
- 33 1 76 21 58 19
- me****@****ome.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- enterome.com
- HQ
- Paris
Enterome Questions
Enterome's helpline number is 33 1 76 21 58 19
Enterome's website is enterome.com
Enterome's LinkedIn profile is https://fr.linkedin.com/company/enterome
Enterome has
42 employees.
View email and phone details for 42
employees at Enterome.
Enterome's industry is
Biotechnology Research
Enterome's top competitors are
Ose Immunotherapeutics,
Phaxiam Therapeutics,
Innate Pharma,
Dna Script,
Treefrog Therapeutics,
Cellectis,
Bioaster,
Coave Therapeutics,
Nanobiotix,
Abivax.
Enterome's support email address is media@enterome.com
Enterome's categories are Biotechnology Research
Enterome's founding year is 2011
